MedTrace Logo

Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma

NCT00006264 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-02-03

No results posted yet for this study

Summary

RATIONALE: Antiviral drugs such as zidovudine and ganciclovir act against viruses and may be an effective treatment for HIV. Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells. Combining these treatments may be effective in treating AIDS-related primary central nervous system lymphoma.

PURPOSE: Phase II trial to study the effectiveness of combining zidovudine, ganciclovir, and interleukin-2 in treating patients who have AIDS-related primary central nervous system lymphoma.

Conditions

Interventions

BIOLOGICAL

aldesleukin

DRUG

ganciclovir

DRUG

zidovudine

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • AIDS Malignancy Consortium

    lead NETWORK

Principal Investigators

  • William J. Harrington, MD · University of Miami Sylvester Comprehensive Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-07-31
Primary Completion
2003-03-31
Completion
2003-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006264 on ClinicalTrials.gov